^
BIOMARKER:
HRD
i
Other names: Homologous Recombination Deficiency
Related biomarkers:
›
HRD
|
Pancreatic Cancer
|
HRD
|
Pancreatic Cancer
|
ABT-888 Resistant: C4 – Case Studies
Clin Cancer Res - 3 weeks
|
ABT-888 Resistant: C4 – Case Studies
Clin Cancer Res - 3 weeks
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
rucaparib Sensitive: B - Late Trials
Cancer Med - 4 weeks
|
rucaparib Sensitive: B - Late Trials
Cancer Med - 4 weeks
|
HRD
|
Fallopian Tube Cancer
|
HRD
|
Fallopian Tube Cancer
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
HRD
|
Peritoneal Cancer
|
HRD
|
Peritoneal Cancer
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
HRD
|
Peritoneal Cancer
|
HRD
|
Peritoneal Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
HRD
|
Fallopian Tube Cancer
|
HRD
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
HRD
|
Prostate Cancer
|
HRD
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
atezolizumab Resistant: B - Late Trials
|
atezolizumab Resistant: B - Late Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
CPB Sensitive: B - Late Trials
|
CPB Sensitive: B - Late Trials
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
bevacizumab + niraparib Sensitive: C2 – Inclusion Criteria
|
bevacizumab + niraparib Sensitive: C2 – Inclusion Criteria
|
HRD
|
NSCLC
|
HRD
|
NSCLC
|
talazoparib Resistant: C3 – Early Trials
|
talazoparib Resistant: C3 – Early Trials
|
HRD
|
Gastric Cancer
|
HRD
|
Gastric Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
pembrolizumab + niraparib Sensitive: C3 – Early Trials
|
pembrolizumab + niraparib Sensitive: C3 – Early Trials
|
HRD
|
Prostate Cancer
|
HRD
|
Prostate Cancer
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
HRD
|
Prostate Cancer
|
HRD
|
Prostate Cancer
|
abiraterone acetate Resistant: C3 – Early Trials
|
abiraterone acetate Resistant: C3 – Early Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
ABT-767 Sensitive: C3 – Early Trials
|
ABT-767 Sensitive: C3 – Early Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
PARP inhibitor Sensitive: C3 – Early Trials
|
PARP inhibitor Sensitive: C3 – Early Trials
|
HRD
|
Prostate Cancer
|
HRD
|
Prostate Cancer
|
talazoparib Sensitive: C3 – Early Trials
|
talazoparib Sensitive: C3 – Early Trials
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials
|
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials
|
